Abstract

Imatinib 40-mg/mL Oral Suspension

Author(s): Allen Loyd V Jr

Issue: Nov/Dec 2016 - Volume 20, Number 6

Page(s): 510

Download in electronic PDF format for $75
  • Imatinib 40-mg/mL Oral Suspension Page 1

Abstract

A formulation for preparing Imatinib 40-mg/mL Oral Suspension. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

  • imatninib
  • formulation
  • hazardous medication
  • antineoplastic agent
  • cancer
  • leukemia
  • gastrointestinal stromal tumor
  • GIST
  • protein tyrosine kinase inhibitor
  • BCR-ABL inhibitor
  • receptor tyrosine kinase inhibitor
  • platelet-derived growth factor receptor
  • PDGF
  • PDGFR
  • stem cell factor inhibitor
  • SCF
  • c-kit inhibitor

Related Categories

  • CANCER AND AIDS
  • FORMULATIONS
  • HAZARDOUS DRUGS

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Nov/Dec 2016
Pg. 510
Imatinib 40-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Mar/Apr 2003
Pg. 106-113
Veterinary Transdermal Medications: A to Z
Author(s): Davidson Gigi S
Jul/Aug 2001
Pg. 310-312
Wetting and/or Solubilizing Agents, Featured Excipient:
Author(s): Allen Loyd V Jr
May/Jun 2004
Pg. 181-185
Compounding in the Pharmacy Curriculum: Beyond the Basics
Author(s): Hinkle Amanda R, Newton Gail D
Nov/Dec 2004
Pg. 462-465
Basics of Compounding for Cough
Author(s): Allen Loyd V Jr
May/Jun 2010
Pg. 248
Sunitinib 10-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Mar/Apr 2011
Pg. 124-128
Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease
Author(s): Corsini Lindsay, Williams LaVonn A
Nov/Dec 2016
Pg. 511
Lapatinib Ditosylate 50-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Jan/Feb 2023
Pg. 53
Erlotinib 10 mg/mL in Ora-Sweet and Ora-Plus
Author(s): Allen Loyd V Jr
Mar/Apr 2024
Pg. 100-109
Compounded Pain Formulations: What is the Evidence?
Author(s): Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Jul/Aug 2014
Pg. 278-286
Compounded Pain Formulations: What is the Evidence?
Author(s): Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Nov/Dec 2016
Pg. 508
Erlotinib 10-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Sep/Oct 2021
Pg. 420
Sorafenib 20-mg/mL in Oil Oral Suspension
Author(s): Allen Loyd V Jr
Jan/Feb 2018
Pg. 59
Voriconazole 40-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Jul/Aug 2011
Pg. 342
Quetiapine Fumarate 40-mg/mL Nonaqueous Oral Suspension
Author(s): Allen Loyd V Jr
Nov/Dec 2011
Pg. 506
Thioguanine 20-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
May/Jun 2010
Pg. 249
Voriconazole 40-mg/mL Oral Suspension, Veterinary
Author(s): Allen Loyd V Jr
Sep/Oct 2010
Pg. 426
Rufinamide 40-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Sep/Oct 2011
Pg. 419
Granisetron Hydrochloride 0.2-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Mar/Apr 2016
Pg. 137-141
Formulation and Stability of Solutions
Author(s): Akers Michael J